Drug intelligence / Profile preview

LYN-064

Development stage: Unknown
Lead developer: Lyndra Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**LYN-064** is an oral monthly contraceptive developed using Lyndra Therapeutics' LYNX™ drug delivery platform, designed to provide steady, consistent drug release over 28 days from a single oral dose. It targets unmet needs in family planning, particularly for women and girls worldwide, with funding from the Bill & Melinda Gates Foundation. The program has been discontinued, and specific details on the active pharmaceutical ingredient or mechanism of action are not publicly detailed beyond the extended-release formulation for contraception.[1][9][13]

Beyond the preview

Go deeper on LYN-064.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYN-064.

Explore the full profile